Skip to main content
Figure 3 | Molecular Neurodegeneration

Figure 3

From: Transient pharmacologic lowering of Aβ production prior to deposition results in sustained reduction of amyloid plaque pathology

Figure 3

Long term LY treatment does not permanently affect APP levels or processing. A. Plasma Aβ40 levels by ELISA after the end of 4–7M LY treatment, (7M), 1 week after termination of treatment, and 2 weeks after termination of treatment. B. Representative anti-APP CT20 immunoblot shows APP levels and accumulation of CTFs after 4-7M LY treatment (tested at 7M). C. Representative anti-APP CT20 immunoblot showing full length APP levels and CTFs after transient 4-7M LY treatment (tested at 15M). D. Quantitative intensity analysis of anti-CT20 immuno-reactive full length APP and APP CTF protein levels normalized to actin.

Back to article page

Molecular Neurodegeneration

ISSN: 1750-1326